Liu Haiying, Wang Zhengyan, Ren Lijun, Zhang Guiqin, Zhao Dan, Guo Yanli, Wang Lijuan, Feng Hong
Department of Respiratory and Critical Care Medicine, The Fourth Hospital of Baotou, Baotou City, Inner Mongolia, China.
Endoscopy Center, The Fourth Hospital of Baotou, Baotou City, Inner Mongolia, China.
Evid Based Complement Alternat Med. 2022 Apr 28;2022:8150444. doi: 10.1155/2022/8150444. eCollection 2022.
To examine the clinical efficacy of budesonide/glycopyrronium bromide/formoterol (Breztri Aerosphere) as an adjunct to acute respiratory distress syndrome (ARDS).
A prospective study enrolled 120 patients with pulmonary endogenous ARDS admitted to the Department of Critical Care Medicine at the Fourth Hospital of Baotou from January 2017 to January 2020, and all enrollments were assigned (1 : 1) to receive conventional treatment (control group) or Breztri Aerosphere (study group).
Breztri Aerosphere was associated with a significantly higher total efficacy versus conventional treatment. Breztri Aerosphere resulted in significantly lower acute physiology and chronic health evaluation scoring system (APACHE II) scores and Murray lung injury scores versus conventional treatment. Both groups saw an increase in the partial pressure of carbon dioxide (PCO2), partial pressure of oxygen (PO2), and oxygen saturation (SaO2) after treatment, with higher levels seen in patients given Breztri Aerosphere. After treatment, systemic vascular resistance (SVR) in both groups rose markedly, with greater elevation witnessed in the study group. The patients given Breztri Aerosphere showed significantly lower levels of pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (MAPA), pulmonary artery wedge pressure (PAWP), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-), and procalcitonin (PCT) versus those receiving conventional treatment. The patients experienced shorter mechanical ventilation time and intensive care unit (ICU) time after treatment of Breztri Aerosphere versus conventional treatment.
Adjuvant therapy with Breztri Aerosphere in ARDS can significantly lower APACHE II scores and Murray lung injury scores, improve blood gas indexes and pulmonary circulation function indexes, and shorten mechanical ventilation time and ICU time, which may be attributed to its improvement of organism inflammation status and reduction of inflammatory factors.
探讨布地奈德/格隆溴铵/福莫特罗（倍卓异气雾剂）作为急性呼吸窘迫综合征（ARDS）辅助治疗的临床疗效。
一项前瞻性研究纳入了2017年1月至2020年1月在包头市第四医院重症医学科住院的120例肺内源性ARDS患者，所有入组患者按1∶1分配接受常规治疗（对照组）或倍卓异气雾剂（研究组）。
与常规治疗相比，倍卓异气雾剂的总有效率显著更高。与常规治疗相比，倍卓异气雾剂导致急性生理与慢性健康状况评分系统（APACHE II）评分和默里肺损伤评分显著更低。两组治疗后二氧化碳分压（PCO2）、氧分压（PO2）和血氧饱和度（SaO2）均升高，接受倍卓异气雾剂治疗的患者升高幅度更大。治疗后，两组的体循环血管阻力（SVR）均显著升高，研究组升高幅度更大。与接受常规治疗的患者相比，接受倍卓异气雾剂治疗的患者肺血管阻力（PVR）、平均肺动脉压（MAPA）、肺动脉楔压（PAWP）、白细胞介素-6（IL-6）、白细胞介素-10（IL-10）、肿瘤坏死因子-α（TNF-α）和降钙素原（PCT）水平显著更低。与常规治疗相比，接受倍卓异气雾剂治疗的患者治疗后机械通气时间和重症监护病房（ICU）时间更短。
倍卓异气雾剂辅助治疗ARDS可显著降低APACHE II评分和默里肺损伤评分，改善血气指标和肺循环功能指标，缩短机械通气时间和ICU时间，这可能归因于其改善机体炎症状态和降低炎症因子水平。
